Stockscreener 앱 받기
818.93
1.30%
-10.81
Lilly Eli Co 주식(LLY)의 최신 뉴스
Eli Lilly price target lowered to $1,015 from $1,025 at Deutsche Bank - Yahoo Finance
Eli Lilly Has a Major Problem With Its Weight Loss Drugs Zepbound and Mounjaro - Yahoo Finance UK
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Eli Lilly grows Milwaukee-area footprint with $40.8M warehouse acquisition — and more - The Business Journals
Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lilly's GLP-1 News - Yahoo Finance UK
Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers - BioSpace
Eli Lilly Stock: Is LLY Stock A Sell After Its Disastrous Third-Quarter Report? - Investor's Business Daily
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip - MSN
ViaNautis signs multi-year collaboration with Eli Lilly and Company - Business Weekly
Friday Five – Humira humbled, Lilly investors get trick instead of treat, Pfizer seeks to show up Starboard… and more - FirstWord Pharma
Eli Lilly and the British government partner to provide GLP-1 weight loss medication to people who have obesity - HR Brew
Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - STAT
Eli Lilly viewed positively despite Mounjaro, Zepbound disappointmentBoA - Proactive Investors USA
Eli Lilly Shares Hit Yearly Low After Disappointing Q3 Earnings - Yahoo Finance
Eli Lilly and Company (NYSE:LLY): Among The 10 Best S&P 500 Stocks to Buy According to Hedge Funds - Insider Monkey
ELI LILLY AND COMPANY : Jefferies remains its Buy rating - Marketscreener.com
Eli Lilly core thesis ‘remains intact’ despite Q3 miss, says JPMorgan - Yahoo Finance
Are Eli Lilly's Lowered Expectations a Reason to Sell? - The Motley Fool
Eli Lilly and Co (LLY) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance
Eli Lilly and Co (LLY): A Strategic SWOT Insight into Pharma's Future - Yahoo Finance UK
Nasdaq edges back from its record as chip companies and Eli Lilly slump - The Decatur Daily
Stocks hit pause after Nasdaq milestone; Eli Lilly earnings underwhelm Wall St. - The Post and Courier
Health Care Down as Eli Lilly Slides -- Health Care Roundup - MarketWatch
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Stock market today: Nasdaq edges back from its record as chip companies and Eli Lilly slump - Oneonta Daily Star
Wall Street indexes edge lower Wednesday as Alphabet jumps and Eli Lilly slumps - Greater Milwaukee Today | GMToday.com
AMD, Eli Lilly slide; Google, Visa rise among Wednesday's afternoon market cap stock movers - Investing.com
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast - Benzinga
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint? - MarketWatch
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed - CNBC
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop - LPHeraldDispatch.com
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried - Yahoo! Voices
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript - The Motley Fool
Eli Lilly plans to begin advertising weight-loss drug Zepbound - Yahoo Finance
Eli Lilly’s slip does not mean the weight loss drug craze is over - Financial Times
Stock movers: Alphabet, Super Micro, Eli Lilly and more - TheStreet
Stock market today: Wall Street wavers as Alphabet jumps on Google profits and Eli Lilly slumps - Ottumwacourier
Eli Lilly had a strong Q3, so why is its stock falling? - Seeking Alpha
Eli Lilly Earnings: Maintaining Our Fair Value and Long-Term GLP-1 Forecast Despite Weaker Q3 - Morningstar
Lilly Cuts Outlook After Obesity Drug Sales Post First Miss - Bloomberg
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling - Reuters
Eli Lilly: The Stock Might Have Peaked (NYSE:LLY) - Seeking Alpha
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks - Yahoo Finance
Lilly cuts outlook on surprising weight-loss drug disappointment - Detroit News
Why Eli Lilly Stock Is Sinking Today - The Motley Fool
Lilly shares tumble on earnings report that falls short of Wall Street expectations - Inside INdiana Business
Stock market today: Wall Street churns near records as Alphabet jumps and Eli Lilly slumps - News-Press Now
Eli Lilly shares tumble as company’s weight-loss drug misses Wall Street sales expectations - The Globe and Mail
Have Eli Lilly's weight-loss drug gains hit a plateau? - Sherwood News
Stock market today: Wall Street churns as Alphabet jumps, Eli Lilly tumbles - Ottumwacourier
Drugmaker Eli Lilly dials back 2024 forecast after 3Q earnings miss - WTHR
Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings miss - Bozeman Daily Chronicle
Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations - Yahoo Finance
Eli Lilly stock tumbles on Q3 miss, Zepbound sales fall short - Yahoo Finance
Lilly shares fall as obesity drug sales miss forecasts - BioPharma Dive
Eli Lilly tumbles as weight loss sales underwhelm, guidance slashed - Proactive Investors USA
Eli Lilly shares tumble as Q3 misses estimates, guidance lowered - Investing.com
AnaptysBio plunges as Eli Lilly drops co's arthritis drug from pipeline - XM
Microsoft and Meta, Eli Lilly, US GDP in Q3: 3 Things - Yahoo Finance
Eli Lilly Shares Tumble After Disappointing Q3 Earnings Report - Lawyer Monthly Magazine
0.01%
0.17%
자본화:
|
볼륨(24시간):